Quantcast

Latest Hypnotics Stories

2011-07-15 19:02:00

POINT RICHMOND, Calif., July 15, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced today plans to reduce operating expenses by eliminating approximately 45% of its workforce following notification from the U.S. Food and Drug Administration (FDA) that the resubmitted New Drug Application (NDA) for Intermezzo® (zolpidem tartrate sublingual tablet), the company's lead product candidate, cannot be approved in its present form....

2011-07-14 22:42:00

POINT RICHMOND, Calif., July 14, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding the resubmitted New Drug Application (NDA) for Intermezzo® (zolpidem tartrate sublingual tablet). In the Complete Response Letter, the FDA confirmed that Transcept has adequately demonstrated that Intermezzo® is efficacious for use...

2011-07-12 19:02:00

POINT RICHMOND, Calif., July 12, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced today that it expects to receive a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding the resubmitted New Drug Application (NDA) for Intermezzo® (zolpidem tartrate sublingual tablet) on or before July 14, 2011, the PDUFA date assigned by the FDA for completion of the Intermezzo® NDA review. The FDA issues a...

2011-07-07 05:30:00

ANAHEIM, Calif., July 7, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it will release second quarter 2011 financial results on Tuesday, July 26, 2011 after the close of the U.S. financial markets. The Company will host a conference call and webcast on Tuesday, July 26, 2011 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the second quarter, as well as current corporate developments. Conference call details:...

2011-06-24 05:10:00

EXTON, Pa., June 24, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of a Pediatric Use Marketing Authorization (PUMA) for Buccolam® (midazolam, oromucosal solution), for treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less...

2011-06-22 12:07:00

BETHLEHEM, Pa., June 22, 2011 /PRNewswire/ -- In a recent announcement by Neurelis, a proprietary intranasal formulation of diazepam (NRL-1) achieved positive clinical results in a Phase I pharmacokinetic study. The propriety formulation was designed and manufactured at Particle Sciences. In the Phase 1 clinical trial NRL-1 demonstrated a pharmacokinetic profile comparable to that reported in the literature for Diastat® (rectal diazepam gel), the only FDA approved...

2011-06-17 13:08:00

JERSEY CITY, N.J., June 17, 2011 /PRNewswire/ -- Aoxing Pharmaceutical (NYSE Amex: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing and distribution of narcotic and pain-management products, announced that its operating subsidiary in China, Hebei Aoxing Pharmaceutical Group Company, has been granted a patent by the State Intellectual Property Office of The People's Republic of China for midazolam maleate oral film. The Chinese...

2011-06-15 06:23:18

(Ivanhoe Newswire)--For people who suffer from insomnia, the metabolism in the brain's frontal cortex increases, making it difficult to fall asleep. According to a recent study, people with primary insomnia may be able to find relief by wearing a cap that cools the brain at night. One way to reduce cerebral metabolic activity is to use a process called "cerebral hypothermia," in which the frontal cerebral thermal transfers to cool the brain. But can this non-pharmaceutical method really cure...

2011-06-14 12:37:00

SAN DIEGO, June 14, 2011 /PRNewswire/ -- Neurelis, Inc. today announced the results of a randomized crossover study in healthy volunteers assessing diazepam pharmacokinetics and bioavailability after administration of their proprietary intranasal diazepam formulations and intravenous injection. The study was designed and conducted in collaboration with investigators at the University of Minnesota. Comparative analysis of the lead intranasal formulation, NRL-1, revealed promising...

2011-06-13 14:43:34

Study finds that treatment with frontal cerebral thermal transfer can eliminate insomnia symptoms People with primary insomnia may be able to find relief by wearing a cap that cools the brain during sleep, suggests a research abstract that will be presented Monday, June 13, in Minneapolis, Minn., at SLEEP 2011, the 25th Anniversary Meeting of the Associated Professional Sleep Societies LLC (APSS). According to the authors, a reduction in metabolism in the brain's frontal cortex occurs while...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related